Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTN3A1 | O00481 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.34 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | FBP1 | P09467 | 1/20 | 0.32 |
| ▸ | CTSA | P10619 | 1/20 | 0.30 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13471227 | 0.88 | BTN3A1 (0.36) | BTN3A1TSHRPPARGNCOA2NCOA1 | |
| SCHEMBL28121930 | 0.88 | BTN3A1 (0.36) | BTN3A1TSHRPPARGNCOA2NCOA1 | |
| SCHEMBL20249575 | 0.86 | BTN3A1 (0.36) | BTN3A1TSHRPPARGNCOA2NCOA1 | |
| SCHEMBL16368121 | 0.86 | BTN3A1 (0.39) | BTN3A1TSHRPPARGNCOA2NCOA1 | |
| SCHEMBL15837310 | 0.86 | BTN3A1 (0.39) | BTN3A1TSHRPPARGNCOA2NCOA1 | |
| SCHEMBL20249592 | 0.86 | BTN3A1 (0.36) | BTN3A1TSHRPPARGNCOA2NCOA1 | |
| SCHEMBL13471051 | 0.83 | BTN3A1 (0.34) | BTN3A1PPARGNCOA2NCOA1RXFP1 | |
| SCHEMBL31211706 | 0.83 | ACE (0.41) | BTN3A1TSHRPPARGNCOA2NCOA1 | |
| SCHEMBL28197101 | 0.82 | BTN3A1 (0.34) | BTN3A1TSHRPPARGNCOA2NCOA1 | |
| SCHEMBL16248429 | 0.82 | TSHR (0.34) | BTN3A1TSHRPPARGNCOA2NCOA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2619215-B1 | AZIDO NUCLEOSIDES AND NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA INC (US) | 2018-09-05 | — | — | EP | disclosed |
| US-20160264610-A1 | AZIDO NUCLEOSIDES AND NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA INC (US) | 2016-09-15 | — | — | US | disclosed |
| US-9346848-B2 | Azido nucleosides and nucleotide analogs | ALIOS BIOPHARMA, INC. (US) | 2016-05-24 | — | — | US | disclosed |
| US-9156872-B2 | 2′-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases | MERCK SHARP & DOHME CORP. (US) | 2015-10-13 | — | — | US | disclosed |
| US-20150183819-A1 | AZIDO NUCLEOSIDES AND NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. | 2015-07-02 | — | — | US | disclosed |
| US-8877731-B2 | Azido nucleosides and nucleotide analogs | ALIOS BIOPHARMA, INC. (US) | 2014-11-04 | — | — | US | disclosed |
| US-20140206640-A1 | 2'-AZIDO SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2014-07-24 | — | — | US | disclosed |
| US-20140206640-A1 | 2'-AZIDO SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2014-07-24 | — | — | US | disclosed |
| US-20120070415-A1 | AZIDO NUCLEOSIDES AND NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160264610-A1 | AZIDO NUCLEOSIDES AND NUCLEOTIDE ANALOGS | PNP, ADA, ADAR | BTN3A1 3276/4885TSHR 2253/4885PPARG 2370/4885 |
| US-20140206640-A1 | 2'-AZIDO SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | ADAR, SLC29A1, SLC28A1 | BTN3A1 2526/4885TSHR 2290/4885PPARG 3632/4885 |
| US-20120070415-A1 | AZIDO NUCLEOSIDES AND NUCLEOTIDE ANALOGS | PNP, ADA, ADAR | BTN3A1 3276/4885TSHR 2253/4885PPARG 2370/4885 |
| US-20150183819-A1 | AZIDO NUCLEOSIDES AND NUCLEOTIDE ANALOGS | PNP, ADA, ADAR | BTN3A1 3276/4885TSHR 2253/4885PPARG 2370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.